Helix BioPharma Corp. (HBPCF)

Helix BioPharma Statistics

Total Valuation

Helix BioPharma has a market cap or net worth of 33.13 million. The enterprise value is 32.97 million.

Market Cap	33.13M
Enterprise Value	32.97M

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+13.57%
Shares Change (QoQ)	-5.97%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	44.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.92
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.86

Financial Position

The company has a current ratio of 0.23

Current Ratio	0.23
Quick Ratio	0.15
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,916.25

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-518.68%
Return on Capital (ROIC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-958,122
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +210.35% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+210.35%
50-Day Moving Average	0.56
200-Day Moving Average	0.39
Relative Strength Index (RSI)	10.24
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.88M
Pretax Income	-6.71M
Net Income	-6.71M
EBITDA	-6.87M
EBIT	-6.88M
Earnings Per Share (EPS)	-0.15

Balance Sheet

Cash & Cash Equivalents	163,617
Total Debt	n/a
Net Cash	163,617
Net Cash Per Share	n/a
Equity (Book Value)	-978,830
Book Value Per Share	-0.02
Working Capital	-986,006

Cash Flow

In the last 12 months, operating cash flow was -3.03 million and capital expenditures -1,435, giving a free cash flow of -3.04 million.

Operating Cash Flow	-3.03M
Capital Expenditures	-1,435
Free Cash Flow	-3.04M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Helix BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.57%
Shareholder Yield	-13.57%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on August 16, 2024. It was a reverse split with a ratio of 0.2.

Last Split Date	Aug 16, 2024
Split Type	Reverse
Split Ratio	0.2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a